{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:38:13Z","timestamp":1762540693027},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Federal Ministry of Education and Research (Bundesministerium f\u00fcr Bildung und Forschung)"},{"name":"COMET Center ONCOTYROL"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.leukres.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T20:38:33Z","timestamp":1505853513000},"page":"84-90","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype"],"prefix":"10.1016","volume":"62","author":[{"given":"Laura","family":"H\u00f6rster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Schildmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Vollmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Rochau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby","family":"Sroczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Wasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Port","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.09.009_bib0005","series-title":"Towards More Precise Medicine for the Diagnosis, Treatment and Prevention of Disease (iPM)","author":"European Science Foundation Personalised Medicine for the European Citizen","year":"2012"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2017.09.009_bib0010","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.metabol.2012.08.016","article-title":"Personalized oncology: recent advances and future challenges","volume":"62","author":"Kalia","year":"2013","journal-title":"Metabolism"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2017.09.009_bib0015","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.metabol.2012.08.023","article-title":"Role of genomics on the path to personalized medicine","volume":"62","author":"Tremblay","year":"2013","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.leukres.2017.09.009_bib0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40273-014-0143-0","article-title":"Is individualized medicine more cost-effective? A systematic review","volume":"32","author":"Hatz","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.leukres.2017.09.009_bib0025","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.leukres.2017.09.009_bib0030","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.leukres.2017.09.009_bib0035","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2017.09.009_bib0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MOH.0b013e32801684c7","article-title":"Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances","volume":"14","author":"Mrozek","year":"2007","journal-title":"Curr. Opin. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2017.09.009_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.leukres.2017.09.009_bib0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2017.09.009_bib0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/j.seminoncol.2008.04.005","article-title":"Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics","volume":"35","author":"Gaidzik","year":"2008","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2017.09.009_bib0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","article-title":"Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications","volume":"29","author":"Marcucci","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2017.09.009_bib0065","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force\u20133","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.leukres.2017.09.009_bib0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.leukres.2017.09.009_bib0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med. Decis. Making"},{"issue":"1","key":"10.1016\/j.leukres.2017.09.009_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\u2013Modeling Studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.leukres.2017.09.009_bib0085","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2","volume":"32","author":"Roberts","year":"2012","journal-title":"Med. Decis. Making"},{"issue":"21","key":"10.1016\/j.leukres.2017.09.009_bib0090","first-page":"80","article-title":"All-Trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia \u2212 results of the AMLSG 07-04 randomized treatment trial","volume":"118","author":"Schlenk","year":"2011","journal-title":"ASH Ann. Meet. Abstracts"},{"key":"10.1016\/j.leukres.2017.09.009_bib0095","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2011"},{"issue":"1","key":"10.1016\/j.leukres.2017.09.009_bib0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0272989X9401400107","article-title":"Determining transition probabilities: confusion and suggestions","volume":"14","author":"Miller","year":"1994","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.leukres.2017.09.009_bib0105","series-title":"Preise. Verbraucherpreisindizes f\u00fcr Deutschland. Jahresbericht","author":"Statistisches Bundesamt","year":"2012"},{"key":"10.1016\/j.leukres.2017.09.009_bib0110","series-title":"Einheitlicher Bewertungsma\u00dfstab. Stand: 4. Quartal 2012","author":"Kassen\u00e4rztliche Bundesvereinigung","year":"2012"},{"key":"10.1016\/j.leukres.2017.09.009_bib0115","series-title":"Vereinbarung \u00fcber die qualifizierte ambulante Versorgung krebskranker Patienten \u201eOnkologie-Vereinbarung (Anlage 7 zu den Bundesmantelvertr\u00e4gen)","author":"GKV-Spitzenverband, Kassen\u00e4rztliche Bundevereinigung","year":"2009"},{"key":"10.1016\/j.leukres.2017.09.009_bib0120","unstructured":"Tree Age Software Inc. 2015."},{"issue":"6","key":"10.1016\/j.leukres.2017.09.009_bib0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force\u20137","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.leukres.2017.09.009_bib0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","article-title":"Modelling in economic evaluation: an unavoidable fact of life","volume":"6","author":"Buxton","year":"1997","journal-title":"Health Econ."},{"issue":"5","key":"10.1016\/j.leukres.2017.09.009_bib0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2710.2003.00458.x","article-title":"Use of pharmacoeconomics in prescribing research. Part 5: modelling\u2013beyond clinical trials","volume":"28","author":"Lang","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.leukres.2017.09.009_bib0140","series-title":"Cost-Effectiveness Thresholds","author":"World Health Organization","year":"2015"},{"issue":"23","key":"10.1016\/j.leukres.2017.09.009_bib0145","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2017.09.009_bib0150","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.09.009_bib0155","article-title":"Dissecting genetic and phenotypic heterogeneity to map molecular phylogenies and deliver personalized outcome and treatment predictions in AML","author":"Papaemmanuil","year":"2015","journal-title":"57th Annual Meeting of the American Society of Hematology; Orlando"},{"key":"10.1016\/j.leukres.2017.09.009_bib0160","article-title":"Personally tailored risk prediction of AML based on comprehensive genomic and clinical data","author":"Gerstung","year":"2015","journal-title":"57th Annual Meeting of the American Society of Hematology. Orlando"},{"issue":"4","key":"10.1016\/j.leukres.2017.09.009_bib0165","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bjh.14076","article-title":"Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia","volume":"174","author":"Cressman","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2017.09.009_bib0170","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00277-012-1530-2","article-title":"Uyl-de Groot CA: real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study","volume":"91","author":"Blommestein","year":"2012","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2017.09.009_bib0175","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.leukres.2012.09.018","article-title":"The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands","volume":"37","author":"Leunis","year":"2013","journal-title":"Leuk. Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T00:18:14Z","timestamp":1656202694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617305179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":35,"alternative-id":["S0145212617305179"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.09.009","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}